Moleculin Announces Full Exercise of Over-Allotment Option

Rhea-AI Summary

Moleculin Biotech, Inc. (Nasdaq: MBRX) has announced that underwriters of its public offering, dated February 3, 2021, fully exercised their option to purchase an additional 2,141,052 shares at $4.75 each. This brings the total shares sold in the offering to 16,414,736, with gross proceeds of approximately $78.0 million before expenses. The offering was made under a shelf registration statement filed with the SEC. Oppenheimer & Co. acted as the sole book-running manager for this transaction.

Positive

• Total of 16,414,736 shares sold in public offering.
• Gross proceeds of approximately $78.0 million before expenses.

Negative

• None.

HOUSTON, Feb. 10, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that the underwriters of its public offering announced February 3, 2021 have exercised in full their option to purchase an additional 2,141,052 shares of common stock at the public offering price of $4.75 per share, less underwriting discount. Combining last week's closing with the effect of the sale of shares pursuant to the over-allotment option, which was completed today, Moleculin sold a total of 16,414,736 shares of common stock in the public offering for gross proceeds of approximately $78.0 million, before deducting underwriting discount and offering expenses.

Oppenheimer & Co. Inc. acted as the sole book-running manager for the offering and Roth Capital Partners, LLC acted as the co-manager for the offering. Maxim Group LLC acted as financial advisor to the Company.

The securities described above were offered by the Company pursuant to a shelf registration statement on Form S-3 (No. 333-235686) originally filed December 23, 2019 with the Securities and Exchange Commission (SEC) and declared effective by the SEC on April 9, 2020. A final prospectus supplement and the accompanying prospectus relating to and describing the terms of the offering was filed with the SEC and is available on the SEC's website at http://www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus may be obtained from Oppenheimer & Co. Inc., Attention: Syndicate Prospectus Department, 85 Broad Street, 26th Floor, New York, New York 10004, by telephone at (212) 667-8055, or by email at EquityProspectus@opco.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Moleculin Biotech, Inc.

Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the development of a broad portfolio of oncology drug candidates for the treatment of highly resistant tumors and viruses. The Company's clinical stage drugs are: Annamycin, a Next Generation Anthracycline, designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity being studied for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as AML, WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic cancer and hematologic malignancies, and WP1220, an analog to WP1066, for the topical treatment of cutaneous T-cell lymphoma. Moleculin is also engaged in preclinical development of additional drug candidates, including other Immune/Transcription Modulators, as well as WP1122 and related compounds capable of Metabolism/Glycosylation Inhibition.

For more information about the Company, please visit http://www.moleculin.com.

Forward-Looking Statements

Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Although Moleculin Biotech believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements as a result of various important factors, including: market conditions that may affect the timing, terms and conditions of the offering, our ability to satisfy the conditions to closing of the offering and other matters affecting our ability to consummate the offering on terms acceptable to us. Moleculin Biotech has attempted to identify forward-looking statements by terminology including ''believes,'' ''estimates,'' ''anticipates,'' ''expects,'' ''plans,'' ''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,'' ''might,'' ''will,'' ''should,'' ''approximately'' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under Item 1A. "Risk Factors" in our most recently filed Form 10-K filed with the Securities and Exchange Commission ("SEC") and updated from time to time in our Form 10-Q filings and in our other public filings with the SEC.  Any forward-looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

Contacts
James Salierno / Carol Ruth
The Ruth Group
973-255-8361 / 917-859-0214
jsalierno@theruthgroup.com 
cruth@theruthgroup.com 
DC:82266802.1

View original content to download multimedia:http://www.prnewswire.com/news-releases/moleculin-announces-full-exercise-of-over-allotment-option-301226279.html

SOURCE Moleculin Biotech, Inc.

FAQ

What did Moleculin Biotech announce on February 10, 2021?

Moleculin Biotech announced the full exercise of the underwriters' over-allotment option from its public offering, resulting in the sale of an additional 2,141,052 shares.

How much money did Moleculin Biotech raise in its latest offering?

Moleculin Biotech raised approximately $78.0 million in gross proceeds from its public offering.

Who managed Moleculin Biotech's public offering announced on February 3, 2021?

Oppenheimer & Co. acted as the sole book-running manager for Moleculin Biotech's public offering.

What was the price per share in Moleculin Biotech's public offering?

The shares in Moleculin Biotech's public offering were priced at $4.75 each.

How many shares were sold in Moleculin Biotech's public offering?

A total of 16,414,736 shares were sold in Moleculin Biotech's public offering.